Compare FNWB & MDXH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
| Metric | FNWB | MDXH |
|---|---|---|
| Founded | 1923 | 2003 |
| Country | United States | Belgium |
| Employees | N/A | N/A |
| Industry | Banks | |
| Sector | Finance | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 79.8M | 183.4M |
| IPO Year | 2012 | 2021 |
| Metric | FNWB | MDXH |
|---|---|---|
| Price | $8.60 | $3.19 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 1 | 3 |
| Target Price | ★ $13.50 | $7.67 |
| AVG Volume (30 Days) | 27.4K | ★ 102.2K |
| Earning Date | 04-23-2026 | 02-26-2026 |
| Dividend Yield | ★ 0.81% | N/A |
| EPS Growth | ★ 36.00 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $176,000.00 | N/A |
| Revenue This Year | $19.24 | $30.78 |
| Revenue Next Year | $8.90 | $18.31 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $7.05 | $1.36 |
| 52 Week High | $10.98 | $5.33 |
| Indicator | FNWB | MDXH |
|---|---|---|
| Relative Strength Index (RSI) | 26.83 | 38.45 |
| Support Level | $8.16 | $3.05 |
| Resistance Level | $9.00 | $3.78 |
| Average True Range (ATR) | 0.30 | 0.14 |
| MACD | -0.04 | -0.01 |
| Stochastic Oscillator | 21.66 | 11.49 |
First Northwest Bancorp is a bank holding company and a financial holding company and is engaged in banking activities through its wholly owned subsidiary, First Fed Bank, as well as certain non-banking financial activities. It includes deposit and lending transactions that are supplemented with other borrowing and investing activities. The bank's principal lending activities are focused on first lien one- to four-family mortgage loans, commercial and multi-family real estate loans, construction and land loans, commercial business loans, and consumer loans.
MDxHealth SA is a multinational healthcare company that provides actionable molecular diagnostic information to personalize the diagnosis and treatment of cancer. Its tests are based on proprietary genomic, epigenetic, and other molecular technologies and assist physicians with the diagnosis of urologic cancers, the prognosis of recurrence risk, and the prediction of response to a specific therapy. It derives revenues from clinical laboratory service testing or the out-licensing of the company's patented DNA methylation platform and biomarkers. Geographically, it derives revenue from the United States of America (USA) and Europe.